// App-Quantinova.ai

40 : Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104- Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials

Researchers

Presenter

  • Arthur Kavanaugh

Principal Investigators

  • Adewale Adebajo

  • Charles Birbara

  • Philip Mease

  • Juan Gomez-Reino

  • Jurgen Wollenhaupt

  • Maurizio Cutolo

  • Georg Schett

  • Eric Lespessailles

  • Melissa McIlraith

  • Chia Chi Hu

  • Christopher Edwards

Medical Centers

  • Radiology, Schon Klinik Hamburg Eilbek, Hamburg, Germany

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • Univ of Toronto, Toronto, Canada

Locations

  • Germany

  • Canada

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved